Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Brent holds above $100 as tanker attacks dampen hopes for Hormuz traffic recovery
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
- This is Morgan Stanley's only preferred sportswear stock
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- White House copper tariff plan stalls amid affordability concerns, sources say
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Seattle Genetics (SGEN) PT Raised to $100 at Cowen
October 30, 2019 7:45 AM EDTCowen analyst Boris peaker raised the price target on Seattle Genetics (NASDAQ: SGEN) to $100.00 (from $80.00) while maintaining a Market Perform rating.... More
H.C. Wainwright Reiterates Buy Rating on Seattle Genetics (SGEN)
October 30, 2019 7:44 AM EDTH.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $140.00 price target on Seattle Genetics (NASDAQ: SGEN). With ongoing clinical momentum and against the backdrop of strong Adcetris sales, Fein believes Seattle Genetics is building a powerful value-driving structure upon its various assets.... More
Seattle Genetics (SGEN) PT Lowered to $107 at RBC Capital
October 30, 2019 6:31 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Seattle Genetics (NASDAQ: SGEN) to $107.00 (from $109.00) while maintaining a Outperform rating.... More
Seattle Genetics (SGEN) Misses Q3 EPS by 19c, Revenues Beat; Raises FY19 Revenue Outlook
October 29, 2019 4:14 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.55), $0.19 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $213.26 million versus the consensus estimate of $211.83 million.
We are executing on our vision of becoming a multi-product global oncology company, recently achieving several important milestones across our late-stage pipeline, said Clay Siegall, Ph.D., President and Chief... More
